According to current diagnosis criteria, first seizures constitute beginning epilepsy when they carry recurrence risks of !60% over the next 10 years. This is frequently the case and warrants AED treatment. Evidence argues against deferring treatment when provoking factors such as sleep deprivation are reported. There are several characteristics of first seizures which markedly increase recurrence risk but not clearly beyond 60%. This includes status epilepticus or seizure flurries at first manifestation or focal semiology indicating focal epilepsy. In this situation, there are still various medical, social and individual aspects supporting early initiation of AED. Modern AED allow this safely and at low dosages.
The first seizure raises the question whether or not to start anticonvulsive treatment. Initiation of antiepileptic drugs (AED) should be carefully considered since epilepsies are usually chronic disorders necessitating long-lasting therapy.
When confronted with a patient's first seizure, two issues have to be addressed. First, acute symptomatic seizures such as alcohol withdrawal seizure or e.g. early posttraumatic seizures have to be identified because the majority of these patients will not develop epilepsy in the future. Secondly, the seizure in question may not be the first seizure at all because many patients do not remember or recognize previous seizures, such as auras, automotor/dialeptic seizures in temporal lobe epilepsy or myoclonic seizures in generalized epilepsy. This underscores the need for a thorough history taken from the patients and their relatives or caregivers. In the case of acute symptomatic seizures when the majority of patients will not develop epilepsy, AED initiation may be postponed but in the latter, epilepsy diagnosis can be established leading to AED administration.
The decision to treat or not is more difficult when a first seizure occurs neither being acute symptomatic nor being preceded by other more subtle seizures. The long term remission and mortality of epilepsy are likely to be independent of the decision to treat the first seizure or to defer AED administration [1] [2] [3] . There is no convincing evidence that AED impact on human epileptogenesis but only ictogenesis. Moreover, epileptogenesis has already taken place long before the first seizure occurs [4] . Therefore, it is the recurrence risk after a first seizure supporting or deferring AED treatment. The importance of an increased recurrence risk led the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) 2005 to reevaluate the definition of epilepsy, enabling diagnosis and justifying treatment of epilepsy already after a first seizure [5] . This was transferred by an ILAE task force in 2014 into a "practical clinical definition of epilepsy" [6] . This definition presumes that epilepsy can be diagnosed after a first seizure when it carries at least 60% recurrence risk over the next 10 years. Establishing the diagnosis leads to AED treatment. In general, different situations can be identified which carry a recurrence risk of !60%, such as first seizures with generalized spike-wave discharges in postictal EEG or remote symptomatic seizures clearly related to a brain lesion weeks or months before [7, 8] .
Additional factors may also reveal increased recurrence risks, such a focal semiology indicating focal epilepsy, neurological deficit on examination as well as a status epilepticus as first manifestation [9, 10] . Especially seizures in the elderly tend to show one or more of these characteristics [11, 12] . However, it may be impossible to estimate exact recurrence risks in many patients' individual settings. This leads to the great challenge to put their risk above or below the cut-off of 60%. It often appears arbitrary to start treatment at a recurrence risk above but withhold it at risks slightly below 60%.
Patients with first unprovoked seizures without structural abnormalities on brain imaging and unremarkable postictal EEG face a recurrence risk as low or as high as 20% À 30% [7, 13] which is about a 10fold increase of the estimated life time risk for epilepsy of 3.5% [14] . Different patients may find different risks unacceptable. Employment status, driving license, stigma in professional or private life or and falls in the elderly may serve as examples for relevant factors encouraging early treatment already at lower recurrence risks. The patients' needs and wishes must be considered in the framework of chances and risks of seizures and AED treatment. This has to be thoroughly discussed with the patients [10] .
Antiepileptic drugs are frequently administered after acute symptomatic seizures during the acute phase of the illness when further seizures could jeopardize recovery from the underlying disease such as seizure related increase of intracerebral pressure in patients with intracerebral hemorrhage [15] . AED are usually withdrawn weeks or months after the acute illness. However, patients with acute symptomatic seizures related to new brain lesions carry an increased risk of about 20%-30% for subsequent epilepsy, so that continuation of anticonvulsive treatment may be considered because of the same reasoning as mentioned above [16] [17] [18] .
Provoking factors such as stress, sleep deprivation, fever or increased alcohol consumption are frequently reported preceding many first seizures. It is then common hope or belief that avoidance of the triggers may warrant seizure freedom in the future. The evidence argues against this assumption. Seizure in the setting of sleep deprivation had only a slightly lower likelihood of seizure recurrence as compared to unprovoked seizures and far greater risks as compared to clear-cut acute symptomatic seizures [19] . Therefore, these circumstances should not defer treatment especially in the presence of possible signs for epilepsy in EEG or imaging [20] . Moreover, complete avoidance of events such stress, fever or sleep deprivation to prevent further seizures will not be successful.
When starting anticonvulsive treatment, it is important to weigh the benefits of reduced recurrence risks against potential adverse events of AED. In addition to efficacy, good tolerability of the drugs, reassuring safety profile and a low potential of pharmacokinetic interactions are crucial for long-term effectiveness. Several newer AED are available which fulfill these requirements facilitating early initiation of long-term AED treatment. This is supported by the fact that low dosages are frequently sufficient in initial monotherapy [21] [22] [23] [24] .
Conclusion
Many first seizures clearly constitute beginning epilepsy because they carry recurrence risks of !60% over the next 10 years. This warrants AED treatment. In addition, there is a wide range of characteristics of first seizures which markedly increase recurrence risk but not clearly beyond 60%. In this situation, there are still various medical, social and individual aspects arguing in favor of early initiation of AED. Modern AED allow this safely and at low dosages.
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